All About Multiple Sclerosis

More MS news articles for July 2003

Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon beta-1b

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12796549&dopt=Abstract

Neurology. 2003 Jun 10;60(11):1849-51
Markovic-Plese S, Bielekova B, Kadom N, Leist TP, Martin R, Frank JA, McFarland HF.
Neuroimmunology Branch (Drs. Markovic-Plese, Bielekova, Leist, Martin, and McFarland) and Laboratory of Diagnostic Radiology Research (Drs. Kadom and Frank), National Institute of Neurological Diseases and Stroke, NIH, Bethesda, MD.

An open-label study was performed to assess the effectiveness of oral azathioprine (AZA) on augmenting the response to interferon beta-1b (IFNbeta-1b) in patients with treatment-refractory relapsing-remitting MS.

Six IFNbeta-1b-treated MS patients with continued disease activity were studied on IFNbeta-1b and AZA therapy for a median period of 15 months.

A 69% reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002).